From the Journals

Adding vasopressin in distributive shock may cut AF risk


 

FROM JAMA


Dr. McIntyre and his colleagues included 23 trials that had enrolled a total of 3,088 patients with distributive shock, a condition in which widespread vasodilation lowers vascular resistances and mean arterial pressure. Sepsis is its most common cause. The current study is one of the first to directly compare the combination of vasopressin and catecholamine to catecholamines alone, which is the current standard of care, the investigators wrote.

They found that the administration of vasopressin was associated with a significant 23% reduction in risk of atrial fibrillation.

“The absolute effect is that 68 fewer people per 1,000 patients will experience atrial fibrillation when vasopressin is added to catecholaminergic vasopressors,” Dr. McIntyre and his coauthors said of the results.

The atrial fibrillation finding was judged to be high-quality evidence, they said, noting that two separate sensitivity analyses confirmed the benefit.

Pages

Recommended Reading

Beware of polypharmacy in patients taking warfarin
MDedge Cardiology
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Cardiology
Takotsubo cardiomyopathy incidence, mortality on the rise
MDedge Cardiology
Permanent His-bundle pacing superior to RV pacing
MDedge Cardiology
MDedge Daily News: Time to let more pregnant women into drug trials?
MDedge Cardiology
Apixaban prevails in study of 163,000 DOAC users
MDedge Cardiology
VIDEO: Screening ECG patch boosts AF diagnoses ninefold
MDedge Cardiology
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Cardiology
Women’s representation in CV drug trials still lagging
MDedge Cardiology
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Cardiology